Home › Funds › ORBIMED ADVISORS LLC › SYRE
ORBIMED ADVISORS LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
ORBIMED ADVISORS LLC reported holding 1,396,151 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$29.0M, representing 0.59% of its reported portfolio and ranking #42 among its reported holdings. ORBIMED ADVISORS LLC has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's SYRE position evolved
ORBIMED ADVISORS LLC first disclosed a stake in SYRE in Q2 2026 at 186,145 shares (US$16.5M). The position peaked in Q3 2026 at 1,396,151 shares, worth US$29.0M. Across 2 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,396,151 shares valued at US$29.0M — an increase of 1,210,006 shares quarter over quarter.. Notable position changes include a 650% increase in Q3 2026 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 186.15K | $16.53M | New |
| Q3 2026 | 1.40M | $29.04M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.20M sh · $309.04M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- Venrock Adviser, LLC 2.49M sh · $221.28M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $168.46M · Q3 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- BRAIDWELL LP 713.96K sh · $63.56M · Q3 2026
- Commodore Capital LP 700.00K sh · $62.32M · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held SYRE?
ORBIMED ADVISORS LLC has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is ORBIMED ADVISORS LLC's current position in SYRE?
As of Q3 2026, ORBIMED ADVISORS LLC holds 1.40M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $29.04M, representing 0.59% of its reported portfolio and ranking #42.
Has ORBIMED ADVISORS LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), ORBIMED ADVISORS LLC increased its position in SYRE. The position peaked in Q3 2026 at 1.40M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.